1. In Vivo
  2. >>COVID-19

Pfizer’s Paxlovid And The Murky World Of Rx Drug Communication

 
• By Sarah Karlin-Smith

Pfizer social media announcement that it’s seeking full approval for the oral COVID antiviral raise questions about where the line is on promotion versus other communications, FDA’s ability to regulate pharma on social media, and the unique considerations of promotion under EUAs.

paxlovid under eua
Pfizer created a video to announce Paxlovid’s NDA submission on 30 June • Source: Shutterstock

Pfizer Inc. announced its submission of a new drug application for its COVID-19 antiviral Paxlovid (nirmatrelvir and ritonavir) 30 June with not just the typical company press release, but also with a silent 30-second video posted on Twitter and Facebook that describes its oral treatment as an “important option,” for individuals at risk of progressing to severe COVID-19 illness.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from COVID-19

More from In Vivo

Rising Leaders 2025: Christina Ziegenberg On Keeping Medtechs Competitive And MDR Compliant

 
• By Ashley Yeo

Good medical device regulation brings balance and builds bridges between healthcare stakeholders. It also accords equal priority to innovation and patient safety. A zero-risk policy cannot achieve these goals, says Christina Ziegenberg, BVMed’s head of regulatory affairs of six years.

Financing Quarterly Statistics, Q1 2025

 
• By Maureen Riordan and Deanna Kamienski

During Q1, biopharmas brought in an aggregate $13.1bn in financing and device company fundraising totaled $5bn; while in vitro diagnostic firms and research tools players raised $418m.

Podcast: Ochre Bio’s Approach To Precision Medicine In Liver Treatment

 
• By David Wild

Ochre Bio co-founder and CSO Quin Wills spoke with In Vivo about the UK-based company's novel approach to finding RNA therapies for chronic liver disease.